Contact
Please use this form to send email to PR contact of this press release:
RedHill Biopharma Announces First Patient Dosed in Phase Ib/II Study with YELIVA® for Multiple Myeloma
TO:
Please use this form to send email to PR contact of this press release:
RedHill Biopharma Announces First Patient Dosed in Phase Ib/II Study with YELIVA® for Multiple Myeloma
TO: